CureVac highlights shift to mRNA technology in seasonal influenza vaccine development: GlobalData
CureVac is among many pharmaceutical companies looking to produce a novel seasonal influenza vaccine via mRNA technology
CureVac is among many pharmaceutical companies looking to produce a novel seasonal influenza vaccine via mRNA technology
Phase 1 dose-escalation study to be conducted at clinical sites in the U.S., the UK, Australia, and the Philippines
The preclinical study provides evidence for strongly improved immune responses with second-generation mRNA backbone jointly developed by CureVac and GSK compared to CureVac’s first-generation mRNA backbone
The company expects to generate an EBITDA margin before special items of around 27 percent in 2021.
WACKER and Helixmith plan to strategically collaborate on the production of a pDNA gene therapy developed by Helixmith for the treatment of diabetic peripheral neuropathy (DPN).
Subscribe To Our Newsletter & Stay Updated